Pacira BioSciences (PCRX) EBITDA Margin (2010 - 2026)

Pacira BioSciences' EBITDA Margin history runs 17 years deep, the most recent figure standing at 3.89% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 271.0% year-over-year to 3.89%; the TTM figure through Mar 2026 stood at 3.28% (up 1532.0% YoY), while the FY2025 annual figure was 2.64%, up 1311.0% from the prior year.
• EBITDA Margin was 3.89% for Q1 2026 at Pacira BioSciences, up from 1.19% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 23.53% in Q2 2023 to a low of 82.77% in Q3 2024.
• Historically, EBITDA Margin has averaged 3.74% across 5 years, with a median of 7.91% in 2024.
• The sharpest annual moves came in 2024 and 2025: EBITDA Margin tumbled 9358 bps in 2024, then surged 8631 bps in 2025.
• A 5-year view of EBITDA Margin shows it stood at 2.06% in 2022, then soared by 787 bps to 18.3% in 2023, then slipped by 28 bps to 13.19% in 2024, then plunged by 91 bps to 1.19% in 2025, then soared by 227 bps to 3.89% in 2026.
• The last three EBITDA Margin figures came in at 3.89% (Q1 2026), 1.19% (Q4 2025), and 3.54% (Q3 2025), per Business Quant data.